Flortanidazole F 18

Drug Profile

Flortanidazole F 18

Alternative Names: 18F-flortanidazole; [18F]-HX4; Flortinidazole (18F)

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Siemens AG
  • Developer Maastricht University; Siemens AG; Threshold Pharmaceuticals
  • Class Nitroimidazoles; Radiopharmaceutical diagnostics; Small molecules; Triazoles
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 29 Jun 2017 Flortanidazole F 18 is available for licensing as of 29 Jun 2017. http://www.thresholdpharm.com/overview-1/
  • 27 Mar 2017 Discontinued - Phase-I for Solid tumours (Diagnosis) in Netherlands (Parenteral)
  • 27 Mar 2017 Discontinued - Phase-II for Head and neck cancer (Diagnosis, Metastatic disease, Recurrent) in Australia and USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top